NCL signs MTA with Cytimmune Sciences for novel nanomedicine

May 21, 2021 , Rockville, MD — Cytimmune and the U.S. Nanotechnology Characterization Laboratory (NCL) have signed a Material Transfer Agreement (MTA). The focus of this agreement is a new nanomedicine construct developed by Cytimmune that simultaneously delivers Interferon gamma (IFN-y) and Tumor Necrosis Factor alpha (TNF alpha) on the same gold nanoparticle. Cytimmune will supply newly formulated therapeutic to the NCL for in vitro studies and characterization. Studies are expected to be initiated in 2021.

About Cytimmune

 Cytimmune is a privately held biotechnology company with operations in Rockville, Maryland, and Boston, Massachusetts. The company is a pioneer in nano-engineering, having developed an in vitro, synthetic immune system used for the rapid creation of fully humanized antibodies, and a set of novel technologies designed to improve the targeting, safety, and efficacy of systemically delivered combination cancer therapies. The company’s pipeline of nanomedicines are part of their IO+ platform — a nanoparticle-based delivery system that targets and attacks solid tumor cancers. Cytimmune’s lead product, CYT-6091, which delivers high-dose Tumor Necrosis Factor Alpha, has successfully completed a phase 1 clinical trial at the U.S. National Cancer Institute. 

About the U.S. Nanotechnology Characterization Laboratory (excerpted from https://ncl.cancer.gov/about-ncl/about-us)

The National Cancer Institute founded the NCL in collaboration with FDA and NIST as a public-private partnership to expedite the development of promising nanotech therapies and diagnostics. The goal of NCL is to facilitate regulatory review by developing an “Assay Cascade” of scientific tests that would help determine the reproducibility, safety, and efficacy of nanomedicines.